Adventrx Pharmaceuticals (ANX)

347 posts / 0 new
Letzter Beitrag
vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Adventrx Pharmaceuticals (ANX)

Diese Firma erfreut sich grosser Aufmerksamkeit. Es gibt Uebernahme gerüchte sowie es wird auf eine FDA Zulassung hingeschaut. Das Jahr hat für Adventrx heute schon gut angefangen. Die Aktie hat sich von einem Tiefpunt 0.12 auf 0.33 hochgearbeitet und war Zeitweise 0.50$ wert. Interessante Geschichte und eine Firma mit Potential. Carl Icahn haltet hier ca. 3.5M Aktien (siehe Top Institutional Holders Grafik). Mal sehn wie es weitergeht.

http://www.adventrx.com

Was macht denn ANX eigentlich genau?

Anwort hier in diesem Video:

http://www.adventrx.com/flash/Vinorelbine.swf

ANX nimmt schon bestehende, zugelassene Medikamente und verbessert diese wie man im Beispiel von Vinorebeline sehen kann. ANX hat eine Emulsion entwickelt welche das Vinorelbine umschliesst und erst beim eintritt in die Krebszelle freilässt. Ergebnis: keine Ausschläge, Rötungen, Schmerzen für den Patienten and der Stelle, wo das Medikament eingespritzt wird.

Termine:

The 12th Annual BioCEO and Investor Conference

Februar 8-9 2010, Waldorf Astoria New York

http://www.ceo.bio.org/opencms/ceo/2010/Companies/PresentingCompanies.html

Adventrx Präsentation am OneMedForum 2010

http://www.ustream.tv/recorded/3959018

FDA Meeting für die 2te NDA Submission

von ANX-530 ca. ende April 2010.

- der Name Exelbine™ für ANX 530 wurde angenommen. 12.03.2010

Keys from the Conf Call on Dec 9th:

First NDA submission expected within the month of December.

Data review underway; FDA meeting is planned

Discussed FDA meeting for ANX-514 NDA in next 30 days to discuss NDA.

Reported that the company has 12 months worth of CASH ON HAND.

Reaffirmed Korean pharma partner, Shin Poong who have 1500 employees.

Discussed the $3 billion market for ANX-514 because of Taxotere acceptance.

Confirmed & Reaffirmed NDA for ANX-530 in 2009.

Discussed business structure and nonemulsion technology, which has little overhead.

Company Snapshot

Developing proprietary products for the treatment of cancer. Lead programs include ANX-530, a novel emulsion formulation of vinorelbine to treat advanced non-small cell lung cancer and advanced or metastatic breast cancer; and ANX-514, a detergent-free emulsion formulation of docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers.

Recent news

Raised approximately $9 million in 2Q09 and 3Q09 financings, providing sufficient capital to support operations well into 2010. NDA for ANX-530 was sendet to the FDA.

Hauptinvestoren:

Alle institutionellen Investoren:

http://www.mffais.com/anx

Summary:

http://www.biocentury.com/companies/Adventrx_Pharmaceuticals_Inc

JohnJohnson
Bild des Benutzers JohnJohnson
Offline
Zuletzt online: 19.01.2010
Mitglied seit: 13.12.2009
Kommentare: 75
NEWS $$$$ ADVENTRX Pharmaceuticals Announces Closing of Fina

NEWS $$$$ ADVENTRX Pharmaceuticals Announces Closing of Financing

SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has completed the previously announced sale of shares of its Series E convertible preferred stock pursuant to a registered direct offering to institutional investors, representing gross proceeds to ADVENTRX of approximately $19 million. ADVENTRX plans to use the net proceeds from the offering to fund activities relating to the commercial launch of ANX-530, including acquiring or developing sales, marketing and distribution capabilities and the associated regulatory compliance infrastructure, and to continue the development of ANX-514 in the United States, and for general corporate purposes

The convertible preferred stock is convertible into shares of ADVENTRX's common stock at the option of the investors at a conversion price of $0.38115 per share and will accrue a 3.73344597664961% cumulative dividend until January 7, 2015. If the convertible preferred stock is converted at any time prior to January 7, 2015, ADVENTRX will pay the holder an amount equal to the total dividend that would accrue on the convertible preferred stock from the conversion date through January 7, 2015, or $186.67 per $1,000 stated value of convertible preferred stock converted, less any dividend payments made with respect to the converted convertible preferred stock. Approximately $3.5 million of the gross proceeds will be placed in an escrow account, which amounts will be released to make the dividend and other payments described above

The investors also will receive warrants to purchase an aggregate of 12,462,285 shares of ADVENTRX's common stock. The warrants will have an exercise price of $0.3499 per share and are exercisable at any time after the closing of the transaction and before the thirty (30) month anniversary of the initial exercise date

The convertible preferred stock and warrants are being offered by ADVENTRX pursuant to effective registration statement(s) on Form S-3 filed with the Securities and Exchange Commission ("SEC"). A prospectus relating to the offering was filed with the SEC on January 4, 2010. Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), acted as the exclusive placement agent for the transaction

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities may only be offered by means of a prospectus. Copies of the prospectus can be obtained directly from Rodman & Renshaw, LLC at 1251 Avenue of the Americas, 20th Floor, New York, NY 10020, or from the SEC's website at http://www.sec.gov/

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at http://www.adventrx.com/

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the potential for regulatory authorities to require additional preclinical work and/or clinical activities to support regulatory filings; the risk the FDA will determine that ANX-530 and Navelbine® are not bioequivalent or for the FDA to require additional preclinical work and/or clinical activities to support the acceptance or approval of an ANX-530 NDA; the risk that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials, and that FDA may require ADVENTRX to perform additional non-clinical or clinical studies; difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ANX-530, including validating commercial manufacturers and suppliers; the risk that ADVENTRX's common stock will be delisted by the NYSE Amex, including as a result of failing to maintain sufficient stockholders' equity or a sufficient stock price; the risk that the provisions of Delaware General Corporation Law will prohibit ADVENTRX from making the cumulative dividend and other payments due its Series E convertible preferred stock (or to the holders thereof), which may be a breach of its certificate of incorporation or other contractual obligations and expose ADVENTRX to corresponding liability; the risk that the performance of third parties on whom ADVENTRX relies to conduct its studies or evaluate the data may be substandard, or they may fail to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and in the prospectus relating to this offering that was filed with the Securities and Exchange Commission on January 4, 2010. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.

DATASOURCE: ADVENTRX Pharmaceuticals, Inc

CONTACT: Brian Culley, Principal Executive Officer of ADVENTRX

Pharmaceuticals, +1-858-552-0866; or Investors, Don Markley of

Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, , for

ADVENTRX Pharmaceuticals, Inc

Web Site: http://www.adventrx.com/

20 GOOD things about ANX:

FROM SOMEONE I TRUST

1) No debt

2) NOT a high float

3) GOOD pre-clinical test results with their drug.

4) NDA then FDA

Mad-Wallstreet
Bild des Benutzers Mad-Wallstreet
Offline
Zuletzt online: 09.10.2011
Mitglied seit: 29.05.2008
Kommentare: 1'493
Adventrx Pharmaceuticals (ANX)

Habe mal recherchiert und mir jetzt ne Tranche gegönnt. Sieht vielversprechend aus.

"Auch aus Steinen, die einem in den Weg gelegt werden, kann man Schönes bauen."

(Johann Wolfgang von Goethe)

JohnJohnson
Bild des Benutzers JohnJohnson
Offline
Zuletzt online: 19.01.2010
Mitglied seit: 13.12.2009
Kommentare: 75
Coming soon............
JohnJohnson
Bild des Benutzers JohnJohnson
Offline
Zuletzt online: 19.01.2010
Mitglied seit: 13.12.2009
Kommentare: 75
Over BILLION in possible new sells, and, the market cap is $

Over BILLION in possible new sells, and, the market cap is $47 million of now.We got a big big winner here.

JohnJohnson
Bild des Benutzers JohnJohnson
Offline
Zuletzt online: 19.01.2010
Mitglied seit: 13.12.2009
Kommentare: 75
NEW BULLISH write UP on ANX - http://www.examiner.com/x-3765
JohnJohnson
Bild des Benutzers JohnJohnson
Offline
Zuletzt online: 19.01.2010
Mitglied seit: 13.12.2009
Kommentare: 75
Finanzierung abgeschossen.Übernahmespekulationen

Finanzierung abgeschossen.Übernahmespekulationen.

Shortys must be cover. posssibe here are Chances for pps about over 2 US$++

ANX - HOT HOT HOT

Mali-P
Bild des Benutzers Mali-P
Offline
Zuletzt online: 12.10.2012
Mitglied seit: 24.08.2009
Kommentare: 1'195
Adventrx Pharmaceuticals (ANX)

:? Wieso ist denn nix los bei denen?

http://www.marketwatch.com/investing/stock/anx

equity holder :"Meine Empfehlung fürs daytraden":

http://www.youtube.com/watch?v=G1RYH9bJkps&feature=related

PowerDau:"Ouw shit, das giit Ohrächräbs!Mach das niemeh"

Mad-Wallstreet
Bild des Benutzers Mad-Wallstreet
Offline
Zuletzt online: 09.10.2011
Mitglied seit: 29.05.2008
Kommentare: 1'493
Re: Finanzierung abgeschossen.Übernahmespekulationen

JohnJohnson wrote:

Finanzierung abgeschossen.Übernahmespekulationen.

Shortys must be cover. posssibe here are Chances for pps about over 2 US$++

ANX - HOT HOT HOT

Woher nimmst du diese Infos? Aus einem US-Forum?

"Auch aus Steinen, die einem in den Weg gelegt werden, kann man Schönes bauen."

(Johann Wolfgang von Goethe)

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Re: Finanzierung abgeschossen.Übernahmespekulationen

Mad-Wallstreet wrote:

JohnJohnson wrote:
Finanzierung abgeschossen.Übernahmespekulationen.

Shortys must be cover. posssibe here are Chances for pps about over 2 US$++

ANX - HOT HOT HOT

Woher nimmst du diese Infos? Aus einem US-Forum?

iHub, aber er konzentriert sich zu sehr auf die pusher meiner meinung nach...

huh er ist ja auch einer. Lol

ADVENTRX Pharmaceuticals Inc

$ 0.32

ANX

Short Interest (Shares Short)

511,400

Days To Cover (Short Interest Ratio)

0.0

Short Percent of Float

0.51 %

Short Interest - Prior

434,600

Short % Increase / Decrease

17.67 %

bubble gum?

Mad-Wallstreet
Bild des Benutzers Mad-Wallstreet
Offline
Zuletzt online: 09.10.2011
Mitglied seit: 29.05.2008
Kommentare: 1'493
Adventrx Pharmaceuticals (ANX)

DALLAS, Jan 8, 2010 (GlobeNewswire via COMTEX News Network) --

BeaconEquity.com announces an investment report featuring biotechnology company Adventrx Pharmaceuticals Inc. (AMEX:ANX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.beaconequity.com/i/ANX

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Adventrx Pharmaceuticals Inc. (ANX) engages in the in-licensing, development and commercialization of cancer-related proprietary drug therapies. The Company seeks to improve upon existing treatments of cancer.

In the report, the analyst notes:

"According to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. If approved by the U.S. Food and Drug Administration (FDA), the market for the Company's drug candidates, has a potential to reach more than $1.0 billion at market saturation.

"The Company's strategy is to take advantage of an effective lifecycle-management technique of reformulating existing successfully marketed drug therapies. Of the top 50 pharmaceutical companies, more than 40% of all drug therapies produced have been reformulated to extend the life of existing marketed drugs between the years 2002 and 2005. Patent expirations and competition are threats to all pharmaceutical companies. Modified and improved existing products have become an important technique as a method of improving revenue stream for longer time periods."

To read the entire report visit: http://www.beaconequity.com/i/ANX

See what investors are saying about these stocks at penny stock forum.

BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Beacon Equity

CONTACT: Beacon Equity Research Jeff Bishop (469)-252-3505 press@beaconequity.com

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.

"Auch aus Steinen, die einem in den Weg gelegt werden, kann man Schönes bauen."

(Johann Wolfgang von Goethe)

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Adventrx Pharmaceuticals (ANX)

^^^das hat nicht viel zu bedeuten BeaconEquity.com wird keinen allzugrossen einfluss ausüben. wichtig ist, dass das medikament zur FDA geschickt wurde um die Zulassung zu prüfen. ich versuche gerade herauszufinden in welchem Zeitrahmen das geschehn wird

und die finanzierung ist abgeschlossen.

bubble gum?

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Adventrx Pharmaceuticals (ANX)

ca. 3-6 Monate aber das potential ist gross für den geduldigen Anleger.

bubble gum?

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Adventrx Pharmaceuticals (ANX)

da kommt gerade richtig dick Volumen rein mal seh ob die 0.33 fallen...

bubble gum?

Mali-P
Bild des Benutzers Mali-P
Offline
Zuletzt online: 12.10.2012
Mitglied seit: 24.08.2009
Kommentare: 1'195
Adventrx Pharmaceuticals (ANX)

:shock:

equity holder :"Meine Empfehlung fürs daytraden":

http://www.youtube.com/watch?v=G1RYH9bJkps&feature=related

PowerDau:"Ouw shit, das giit Ohrächräbs!Mach das niemeh"

Miami
Bild des Benutzers Miami
Offline
Zuletzt online: 18.09.2015
Mitglied seit: 14.05.2009
Kommentare: 772
Adventrx Pharmaceuticals (ANX)

Vagnum wrote:

da kommt gerade richtig dick Volumen rein mal seh ob die 0.33 fallen...

Orderbook? Volumen? hat jemand einen Link zur Hand?

Geld ist immer vorhanden, aber die Taschen wechseln

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Adventrx Pharmaceuticals (ANX)

Miami wrote:

Vagnum wrote:
da kommt gerade richtig dick Volumen rein mal seh ob die 0.33 fallen...

Orderbook? Volumen? hat jemand einen Link zur Hand?

ich hab leider weder für den schweizer noch für den amerikanischen markt ein orderbuch.

Volumen ist 34'959'098

17 600 000 buy

14 000 000 sell

ich hab jede menge links zur Hand aber was genau brauchst du?

bubble gum?

Miami
Bild des Benutzers Miami
Offline
Zuletzt online: 18.09.2015
Mitglied seit: 14.05.2009
Kommentare: 772
Adventrx Pharmaceuticals (ANX)

Vagnum wrote:

Miami wrote:
Vagnum wrote:
da kommt gerade richtig dick Volumen rein mal seh ob die 0.33 fallen...

Orderbook? Volumen? hat jemand einen Link zur Hand?

ich hab leider weder für den schweizer noch für den amerikanischen markt ein orderbuch.

Volumen ist 34'959'098

17 600 000 buy

14 000 000 sell

ich hab jede menge links zur Hand aber was genau brauchst du?

Hi Vagnum - vielen Dank, nun habe in Zwischenzeit auch schon einige Seiten entdeckt - hast eine gute zur Hand mit (average Volumen, anz. Aktien etc) - bist du investiert? Zock oder mit grösserem Betrag?

Geld ist immer vorhanden, aber die Taschen wechseln

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Adventrx Pharmaceuticals (ANX)

Miami wrote:

Vagnum wrote:
Miami wrote:
Vagnum wrote:
da kommt gerade richtig dick Volumen rein mal seh ob die 0.33 fallen...

Orderbook? Volumen? hat jemand einen Link zur Hand?

ich hab leider weder für den schweizer noch für den amerikanischen markt ein orderbuch.

Volumen ist 34'959'098

17 600 000 buy

14 000 000 sell

ich hab jede menge links zur Hand aber was genau brauchst du?

Hi Vagnum - vielen Dank, nun habe in Zwischenzeit auch schon einige Seiten entdeckt - hast eine gute zur Hand mit (average Volumen, anz. Aktien etc) - bist du investiert? Zock oder mit grösserem Betrag?

Hallo Miami

ich arbeite mit:

http://www.google.com/finance

www.nasdaq.com

www.investorshub.com

bei investosrhub nutze ich nur die tools.

investiert bin ich noch nicht, habe sie vor ca. 2 wochen für 0.39 gekauft und für 0.44 wieder gegeben es kann noch ne weile dauern bis die FDA entscheidung kommt, ich bleibe aber dran. im moment ist das spekulatiosgetrieben und am Montag hat die Firma einen Event.

gruss

bubble gum?

JohnJohnson
Bild des Benutzers JohnJohnson
Offline
Zuletzt online: 19.01.2010
Mitglied seit: 13.12.2009
Kommentare: 75
ANX - Hot on Walstreet Tip

Power Hour $$$$[/b]

JohnJohnson
Bild des Benutzers JohnJohnson
Offline
Zuletzt online: 19.01.2010
Mitglied seit: 13.12.2009
Kommentare: 75
ANX

MACD and RSI pointing north again....beautiful!!!!!

Next week more 300%++ on News

JohnJohnson
Bild des Benutzers JohnJohnson
Offline
Zuletzt online: 19.01.2010
Mitglied seit: 13.12.2009
Kommentare: 75
NEWS $Press Release Source: Beacon Equity On Friday January

NEWS $$ Press Release Source: Beacon Equity On Friday January 8, 2010, 6:50 am EST

DALLAS, Jan. 8, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotechnology company Adventrx Pharmaceuticals Inc. (AMEX:ANX - News). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.beaconequity.com/i/ANX

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Adventrx Pharmaceuticals Inc. (ANX) engages in the in-licensing, development and commercialization of cancer-related proprietary drug therapies. The Company seeks to improve upon existing treatments of cancer.

In the report, the analyst notes:

"According to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. If approved by the U.S. Food and Drug Administration (FDA), the market for the Company's drug candidates, has a potential to reach more than $1.0 billion at market saturation.

"The Company's strategy is to take advantage of an effective lifecycle-management technique of reformulating existing successfully marketed drug therapies. Of the top 50 pharmaceutical companies, more than 40% of all drug therapies produced have been reformulated to extend the life of existing marketed drugs between the years 2002 and 2005. Patent expirations and competition are threats to all pharmaceutical companies. Modified and improved existing products have become an important technique as a method of improving revenue stream for longer time periods."

To read the entire report visit: http://www.beaconequity.com/i/ANX

See what investors are saying about these stocks at penny stock forum.

BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Adventrx Pharmaceuticals (ANX)

Videopräsentation von Vinorelbine, dem der FDA gesendeten Kanditaten von Adventrx.

http://www.adventrx.com/flash/Vinorelbine.swf

bubble gum?

Mali-P
Bild des Benutzers Mali-P
Offline
Zuletzt online: 12.10.2012
Mitglied seit: 24.08.2009
Kommentare: 1'195
Adventrx Pharmaceuticals (ANX)

8) Gut gibts den liveticker.....erst war ich uh huere skeptisch, nun gespannt WinkWink

Nein ich bin nicht drinn, aber freue mich wenn andere Geld machen und ich ihnen zuschauen darf Biggrin

equity holder :"Meine Empfehlung fürs daytraden":

http://www.youtube.com/watch?v=G1RYH9bJkps&feature=related

PowerDau:"Ouw shit, das giit Ohrächräbs!Mach das niemeh"

JohnJohnson
Bild des Benutzers JohnJohnson
Offline
Zuletzt online: 19.01.2010
Mitglied seit: 13.12.2009
Kommentare: 75
ANX - Hot on Walstreet Tip

ALL Longs need to watch this: http://www.adventrx.com/flash/Vinorelbine.swf

OneMedForum Finance Conference 2010

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

http://www.onemedplace.com/onemedforum/

Held annually in San Francisco, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners. Over 100 company presentations will occur by some of the most promising - and typically least recognized - companies in the world. Recognizing the impacts and opportunities connected to healthcare reform and the stimulus package, we have added a third day dedicated to Health Information. Join us at The Sir Francis Drake Hotel, as it will be the destination for those who are interested in emerging healthcare and life sciences companies.

PRESENTING COMPANIES : http://www.onemedplace.com/onemedforum/companies.php

http://finance.aol.com/company/adventrx-pharmaceuticals-inc/anx/ase/inst...

Mali-P
Bild des Benutzers Mali-P
Offline
Zuletzt online: 12.10.2012
Mitglied seit: 24.08.2009
Kommentare: 1'195
Adventrx Pharmaceuticals (ANX)

Hey Johnson Johnson, kannst du auch deutsch? kann kaum englisch:)

danke nochmals!

equity holder :"Meine Empfehlung fürs daytraden":

http://www.youtube.com/watch?v=G1RYH9bJkps&feature=related

PowerDau:"Ouw shit, das giit Ohrächräbs!Mach das niemeh"

JohnJohnson
Bild des Benutzers JohnJohnson
Offline
Zuletzt online: 19.01.2010
Mitglied seit: 13.12.2009
Kommentare: 75
ANX / Link for Wednesday !

ANX / Link for Wednesday !

Webcast

ADVENTRX PHARMACEUTICALS INC at OneMedPlace Finance Forum (Live)

01/13/10 at 4:30 p.m. PT

http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-IRHome

http://ir.adventrx.com/phoenix.zhtml?p=irol-eventDetails&c=75414&eventID...

sascha77
Bild des Benutzers sascha77
Offline
Zuletzt online: 10.09.2012
Mitglied seit: 19.05.2006
Kommentare: 543
Adventrx Pharmaceuticals (ANX)

wer ist zu welchen EP's dabei wenn ich fragen darf

gruess sascha

JohnJohnson
Bild des Benutzers JohnJohnson
Offline
Zuletzt online: 19.01.2010
Mitglied seit: 13.12.2009
Kommentare: 75
M.E. Garza's article on ANX from December 29, 2009:

M.E. Garza's article on ANX from December 29, 2009:

http://seekingalpha.com/article/180106-adventrx-pharmaceuticals-gains-ne...

A quote from BRIAN M. CULLEY (Principal Executive Officer) from a Wall Street interview held on October 19, 2009:

"TWST: How would you like to see the company evolve over the next couple of years?

Mr. Culley: We’re strongly committed to creating value for ADVENTRX stockholders. That might mean we will be acquired or will remain as an independent business, and we will make those determinations as we grow, but we will always make the decision that we believe maximizes our value on a risk-adjusted basis".

http://www.adventrx.com/assets/pdfs/ANX-TWST-Oct09-FINAL.pdf

sascha77
Bild des Benutzers sascha77
Offline
Zuletzt online: 10.09.2012
Mitglied seit: 19.05.2006
Kommentare: 543
Re: M.E. Garza's article on ANX from December 29, 2009:

JohnJohnson wrote:

M.E. Garza's article on ANX from December 29, 2009:

http://seekingalpha.com/article/180106-adventrx-pharmaceuticals-gains-ne...

A quote from BRIAN M. CULLEY (Principal Executive Officer) from a Wall Street interview held on October 19, 2009:

"TWST: How would you like to see the company evolve over the next couple of years?

Mr. Culley: We’re strongly committed to creating value for ADVENTRX stockholders. That might mean we will be acquired or will remain as an independent business, and we will make those determinations as we grow, but we will always make the decision that we believe maximizes our value on a risk-adjusted basis".

http://www.adventrx.com/assets/pdfs/ANX-TWST-Oct09-FINAL.pdf

have you bought some shares? If yes, what your average price? whats your price target?

best regards sascha

JohnJohnson
Bild des Benutzers JohnJohnson
Offline
Zuletzt online: 19.01.2010
Mitglied seit: 13.12.2009
Kommentare: 75
ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) Reuters ProVestor

ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) Reuters ProVestor Plus Company Report

Industry Profitability

8 January, 2010 Page 8

TTM = Trailing Twelve Month. MRQ = Most Recent Quarter.

Financial Strength

ANX Industry Sector S&P 500 Company Rank in Industry

Quick Ratio 1.7 3.1 2.3 1.5 51

Current Ratio 1.7 3.7 3.0 2.0 46

Total Debt to Equity 0.0 0.4 0.5 0.8 NA

Long Term Debt to Equity 0.0 0.3 0.4 0.6 NA

Interest Coverage for Trailing Twelve Months (338.9) 2.1 19.3 10.9 5

Worst Best

Values are for Most Recent Quarter unless noted otherwise. ADVENTRX Pharmaceuticals, Inc. is less leveraged than the average for the

Biotechnology & Drugs industry.

Growth Rates (%)

% Growth Rate ANX Industry Sector S&P 500 Company Rank in Industry

Sales Growth For Most Recent Quarter NA 14.6 6.0 (6.7) NA

Sales Growth For Trailing 12 Months (40.0) 11.1 3.4 (5.6) 18

Sales Growth For Past 5 Years 162.7 27.3 15.3 13.0 98

Capital Spending Growth for Past 5 Years 32.4 10.0 6.5 12.2 76

EPS Growth for Most Recent Quarter 69.6 25.5 23.6 (0.3) 77

EPS Growth for Trailing Twelve Months 33.0 17.7 16.0 (15.0) 62

EPS Growth for Past 5 Years NA 30.5 20.8 16.8 NA

Worst Best

ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) Reuters ProVestor Plus Company Report

Annual Financial Statements

8 January, 2010 Page 9

Years are Fiscal Years.

Currency in Thousands of U.S. Dollars (except per share values). Shares in Thousands.

Annual Income Statement

2001 2002 2003 2004 2005 2006 2007 2008

12 Months 12 Months 12 Months 12 Months 12 Months 12 Months 12 Months 12 Months

Dec. 31, 2001 Dec. 31, 2002 Dec. 31, 2003 Dec. 31, 2004 Dec. 31, 2005 Dec. 31, 2006 Dec. 31, 2007 Dec. 31, 2008

Restated as of Restated as of

Dec. 31, 2007 Dec. 31, 2007

Licensing revenue $0 $46 $4 $0 $0 $0 $500 $500

Total Revenue $0 $46 $4 $0 $0 $0 $500 $500

General/Admin. $2,038 $1,388 $1,586 $4,018 $4,901 $7,236 $8,679 $9,720

Research/Development 946 283 749 2,744 8,682 12,001 15,934 17,922

Depreciation/Amort. 7,672 428 9 41 116 177 198 168

Interest Expense 12 54 1 0 0 0 0 0

In process research and

development NA NA NA 0 0 10,422 0 0

Goodwill Impairment 5,702 NA NA 0 NA NA 0 0

Total Operating Expense $16,370 $2,153 $2,345 $6,803 $13,699 $29,836 $24,811 $27,810

Interest Income $32 $1 $9 $103 $496 $1,165 $2,169 $550

Other Income NA NA NA NA NA NA 0 112

Net Income Before Taxes ($16,338) ($2,106) ($2,332) ($6,700) ($13,203) ($28,671) ($22,142) ($26,648)

Net Income After Taxes ($16,338) ($2,106) ($2,332) ($6,700) ($13,203) ($28,671) ($22,142) ($26,648)

Net Income Before Extra. Items ($16,338) ($2,106) ($2,332) ($6,700) ($13,203) ($28,671) ($22,142) ($26,648)

Net Income ($16,338) ($2,106) ($2,332) ($6,700) ($13,203) ($28,671) ($22,142) ($26,648)

Preferred Dividends ($256) ($242) ($38) $0 $0 $0 $0 $0

EPS Reconciliation

2001 2002 2003 2004 2005 2006 2007 2008

Income Available to Com Excl

ExtraOrd ($16,594) ($2,348) ($2,370) ($6,700) ($13,203) ($28,671) ($22,142) ($26,648)

Income Available to Com Incl

ExtraOrd ($16,594) ($2,348) ($2,370) ($6,700) ($13,203) ($28,671) ($22,142) ($26,648)

Basic Weighted Average Shares 14,805 15,682 31,798 50,720 59,828 73,988 89,913 90,253

Basic EPS Excluding ExtraOrdinary

Items ($1.12) ($0.15) ($0.07) ($0.13) ($0.22) ($0.39) ($0.25) ($0.30)

Basic EPS Including ExtraOrdinary

Items ($1.12) ($0.15) ($0.07) ($0.13) ($0.22) ($0.39) ($0.25) ($0.30)

Diluted Net Income ($16,594) ($2,348) ($2,370) ($6,700) ($13,203) ($28,671) ($22,142) ($26,648)

Diluted Weighted Average Shares 14,805 15,682 31,798 50,720 59,828 73,988 89,913 90,253

Diluted EPS Excluding ExtraOrd Items ($1.12) ($0.15) ($0.07) ($0.13) ($0.22) ($0.39) ($0.25) ($0.30)

Diluted EPS Including ExtraOrd Items ($1.12) ($0.15) ($0.07) ($0.13) ($0.22) ($0.39) ($0.25) ($0.30)

Normalized Income Before Taxes ($3,033) ($2,106) ($2,332) ($6,700) ($13,203) ($18,249) ($22,142) ($26,648)

Normalized Income After Taxes ($3,033) ($2,106) ($2,332) ($6,700) ($13,203) ($18,249) ($22,142) ($26,648)

Normalized Inc. Avail to Com. ($3,289) ($2,348) ($2,370) ($6,700) ($13,203) ($18,249) ($22,142) ($26,648)

Basic Normalized EPS ($0.22) ($0.15) ($0.07) ($0.13) ($0.22) ($0.25) ($0.25) ($0.30)

Diluted Normalized EPS ($0.22) ($0.15) ($0.07) ($0.13) ($0.22) ($0.25) ($0.25) ($0.30)

Trend Graphs on next page

ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) Reuters ProVestor Plus Company Report

Annual Financial Statements

8 January, 2010 Page 10

Years are Fiscal Years.

Currency in Thousands of U.S. Dollars (except per share values). Shares in Thousands.

Income Statement Trend Graphs

Bar graphs of specific Income Statement items can be used to help in identifying volatility.

Fiscal Year 2008

Fiscal Year 2007

Fiscal Year 2006

Fiscal Year 2005

Fiscal Year 2004

Fiscal Year 2003

Fiscal Year 2002

Fiscal Year 2001

NM

NM

NM

NM

NM

NM

NM

NM

($0.30)

($0.25)

($0.39)

($0.22)

($0.13)

($0.07)

($0.15)

($1.12)

$500

$500

$0

$0

$0

$4

$46

$0

NA

NA

NM

NM

NM

NA

NA

NM

Annual EBITD Margin (%) EPS Diluted (Excl. Extraord.) Net Annual Revenue Annual Gross Margin (%)

ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) Reuters ProVestor Plus Company Report

Annual Financial Statements

8 January, 2010 Page 11

Years are Fiscal Years.

Currency in Thousands of U.S. Dollars. Shares in Thousands.

Annual Balance Sheet

2001 2002 2003 2004 2005 2006 2007 2008

As of As of As of As of As of As of As of As of

Dec. 31, 2001 Dec. 31, 2002 Dec. 31, 2003 Dec. 31, 2004 Dec. 31, 2005 Dec. 31, 2006 Dec. 31, 2007 Dec. 31, 2008

Reclassified as of

Assets Dec. 31, 2007

Cash and cash equivalents $164 $104 $4,226 $13,032 $14,635 $25,974 $14,781 $9,850

Shortterm investments NA NA NA 0 7,958 25,771 18,682 0

Notes Rcvbl. 36 0 NA NA NA NA NA NA

Prepaid Expenses 0 0 28 115 256 511 616 478

Advances to Emp. 30 0 NA NA NA NA NA NA

Interest and other receivables NA NA 0 11 10 80 72 122

Assets Available for Sale NA NA 0 108 0 NA NA NA

Total Current Assets $230 $104 $4,254 $13,266 $22,859 $52,336 $34,151 $10,450

Furnit./Equip. $32 $32 $48 $333 $513 $651 $755 $720

Computer Softwar 9 12 12 12 65 99 122 103

Depreciation (28) (30) (39) (60) (170) (347) (545) (625)

Other Assets 34 13 8 57 355 58 58 61

Total Assets $277 $131 $4,283 $13,608 $23,622 $52,797 $34,541 $10,709

Liabilities

Payable/Accrued $430 $579 $90 $532 $593 $480 $552 $1,721

Accrued Salary 304 115 0 57 173 293 623 915

Accrued Liabilities NA NA 0 629 930 1,675 2,318 2,077

Curr.Port.NP 54 197 0 NA NA NA NA NA

Accrued Dividend 128 35 73 0 NA NA NA NA

Warranty Liability NA NA NA 0 29,696 NA NA NA

Total Current Liabilities $916 $926 $163 $1,218 $31,392 $2,448 $3,493 $4,713

Notes Payable $0 $57 $0 NA NA NA NA NA

Total Long Term Debt 0 57 0 NA NA NA NA NA

Other Long Term Liabilites NA NA NA 0 57 36 14 0

Total Liabilities $916 $983 $163 $1,218 $31,449 $2,484 $3,507 $4,713

Shareholder Equity

Sr. B Conv. Prfd $0 $2 $2 $0 $0 NA NA NA

Sr. C Conv. Prfd 0 1 0 0 0 NA NA NA

Common Stock 15 17 42 54 67 90 90 90

Paid in Capital 23,390 25,276 32,557 47,553 52,105 127,284 130,141 131,751

Accum Deficit (24,043) (26,149) (28,481) (35,182) (59,965) (77,057) (99,199) (125,846)

Treasury Stock NA NA 0 (35) (35) NA NA NA

Accumulated other comprehensive

income ( NA NA NA 0 (2) (2) 3 0

Total Equity ($638) ($853) $4,120 $12,390 ($7,830) $50,315 $31,035 $5,995

Total Liabilities & Shareholders'

Equity $278 $130 $4,283 $13,608 $23,619 $52,799 $34,542 $10,708

S/O-Common Stock 15,005 17,496 42,492 53,834 56,506 89,677 90,253 90,253

Total Common Shares

Outstanding 15,005 17,496 42,492 53,834 56,506 89,677 90,253 90,253

T/S-Common Stock NA NA 0 23 23 0 0 0

S/O-Sr. A. Conv. Prfd. Stk. 3 0 0 0 NA NA NA NA

S/O-Sr. B. Conv. Prfd. Stk. 200 200 200 0 NA NA NA NA

S/O-Sr. C. Conv. Prfd. Stk. 0 70 0 0 NA NA NA NA

Total Preferred Shares Outstanding 203 271 200 0 NA NA NA NA

Trend Graphs on next page

ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) Reuters ProVestor Plus Company Report

Annual Financial Statements

8 January, 2010 Page 12

Years are Fiscal Years.

Currency in Thousands of U.S. Dollars. Shares in Thousands.

Balance Sheet Trend Graphs

Bar graphs of specific Balance Sheet items can be used to help in identifying volatility.

Fiscal Year 2008

Fiscal Year 2007

Fiscal Year 2006

Fiscal Year 2005

Fiscal Year 2004

Fiscal Year 2003

Fiscal Year 2002

Fiscal Year 2001

$9,850

$14,781

$25,974

$14,635

$13,032

$4,226

$104

$164

$4,713

$3,507

$2,484

$31,449

$1,218

$163

$983

$916

$5,995

$31,035

$50,315

($7,830)

$12,390

$4,120

($853)

($638)

90,253

90,253

89,677

56,506

53,834

42,492

17,496

15,005

Cash and Equivalents Total Liabilities Total Equity Shares Outstanding

ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) Reuters ProVestor Plus Company Report

Annual Financial Statements

8 January, 2010 Page 13

Years are Fiscal Years.

Currency in Thousands of U.S. Dollars.

Annual Cash Flow Statement

2001 2002 2003 2004 2005 2006 2007 2008

12 Months 12 Months 12 Months 12 Months 12 Months 12 Months 12 Months 12 Months

Dec. 31, 2001 Dec. 31, 2002 Dec. 31, 2003 Dec. 31, 2004 Dec. 31, 2005 Dec. 31, 2006 Dec. 31, 2007 Dec. 31, 2008

Reclassified as of Reclassified as of

Cash From (Used By) Operations Dec. 31, 2007 Dec. 31, 2007

Net Income ($16,339) ($2,106) ($2,332) ($6,701) ($13,203) ($28,672) ($22,142) ($26,647)

Depreciation 7,618 33 9 41 116 177 198 168

Gain on disposal of fixed assets NA NA NA NA NA NA 0 (4)

Forgiveness Advance 0 30 0 0 NA NA NA NA

Goodwill Impairment 5,702 NA 0 0 NA NA NA NA

Write off of Assets AFS NA NA 0 0 108 0 0 NA

In-process research and

development NA NA NA NA 0 10,422 0 NA

Amort. Debt Discount 54 396 0 0 NA NA NA NA

Expense Paid Warrant 167 163 157 86 NA NA NA NA

Expense Paid Prfd. 137 6 0 0 NA NA NA NA

Exp. Rel. to Options 0 329 286 525 995 1,894 2,414 1,606

Expenses Rel. Options issd Non

Employees NA NA 0 0 94 104 2 5

Expenses paid by issuance of

common NA NA 0 0 102 147 78 0

Accretion of Discounts NA NA 0 0 (112) (243) (1,042) (208)

Issuance of Common 387 12 207 0 NA NA NA NA

Prepaid Assets NA 0 (23) (255) (281) (107) (174) 86

Other Assets 12 (9) 0 0 57 (21) (21) (14)

Increase in accounts payable and

accrued 550 44 (550) 1,128 479 525 1,044 1,221

Cash from Operating Activities ($1,712) ($1,102) ($2,246) ($5,176) ($11,645) ($15,774) ($19,643) ($23,787)

Plus: Cash From (Used By) Investment Activities

Capital Expenditure ($16) ($2) ($16) ($306) ($238) ($172) ($127) ($65)

Cash paid for acquisitions net of

cash NA NA NA NA 0 (32) 0 NA

Proceeds from sale of property and

equip NA NA NA NA NA NA 0 34

Mat. Certificates 1,016 NA NA NA NA NA NA NA

Proceeds from Sale of Short Term

Inv. NA NA 0 0 5,275 15,030 59,240 33,244

Purchase of Short Term Invesetment NA NA 0 0 (13,123) (32,600) (51,104) (14,356)

Cash Acquired (35) NA NA NA NA NA NA NA

Notes Rcvbl. NA 36 0 NA NA NA NA NA

Cash from Investing Activities $965 $34 ($16) ($306) ($8,086) ($17,774) $8,009 $18,857

Plus: Cash From (Used By) Financing Activities

Finance Payment NA NA $0 ($1,367) ($1,883) ($3,135) $0 NA

Proceeds from sale of common stock NA 0 6,590 15,626 19,999 39,999 0 NA

Sale of Prfd. Stock 0 1,002 0 NA NA NA NA NA

Exercise of Stock Options NA NA 0 0 145 126 442 0

Exerecise of Warrant 48 287 NA 27 3,073 7,898 0 NA

Purchase of Warrants (55) NA 50 0 0 NA NA NA

Issuance of LT Debt 450 NA NA NA NA NA NA NA

Payment of LT Debt NA (280) (254) 0 NA NA NA NA

Cash from Financing Activities $443 $1,009 $6,386 $14,286 $21,334 $44,888 $442 $0

Equals: Increase (Decrease) In Cash

Net Change in Cash ($303) ($61) $4,122 $8,806 $1,602 $11,339 ($11,193) ($4,931)

Net Cash - Beginning Balance $468 $164 $104 $4,226 $13,032 $14,635 $25,974 $14,781

Net Cash - Ending Balance 164 104 4,226 13,032 14,634 25,974 14,781 9,850

Cash Interest Paid 3 7 1 0 0 0 0 0

Trend Graphs on next page

Seiten